Q1 Earnings Forecast for CAPR Issued By HC Wainwright

Capricor Therapeutics, Inc. (NASDAQ:CAPR) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Capricor Therapeutics in a research report issued on Friday, March 13th. HC Wainwright analyst J. Pantginis anticipates that the biotechnology company will post earnings of ($0.59) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Wednesday, March 18th. The biotechnology company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11).

CAPR has been the subject of a number of other research reports. Alliance Global Partners reissued a “buy” rating on shares of Capricor Therapeutics in a research note on Wednesday, December 3rd. B. Riley Financial increased their price target on Capricor Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a report on Friday. Wall Street Zen lowered Capricor Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, January 11th. Oppenheimer boosted their price objective on Capricor Therapeutics from $22.00 to $54.00 and gave the company an “outperform” rating in a research note on Monday, December 8th. Finally, UBS Group set a $50.00 target price on Capricor Therapeutics in a research report on Monday, December 15th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.09.

Capricor Therapeutics Stock Performance

NASDAQ:CAPR opened at $30.56 on Monday. The firm’s fifty day moving average is $25.82 and its 200-day moving average is $16.83. Capricor Therapeutics has a 52 week low of $4.30 and a 52 week high of $40.37. The firm has a market cap of $1.69 billion, a P/E ratio of -13.52 and a beta of 0.37.

Institutional Trading of Capricor Therapeutics

Large investors have recently made changes to their positions in the company. Royal Bank of Canada grew its stake in Capricor Therapeutics by 12.4% in the fourth quarter. Royal Bank of Canada now owns 5,040 shares of the biotechnology company’s stock valued at $146,000 after acquiring an additional 557 shares during the period. ACT Capital Management LLC acquired a new position in shares of Capricor Therapeutics during the fourth quarter worth approximately $43,000. Nuveen LLC raised its position in shares of Capricor Therapeutics by 2.1% during the fourth quarter. Nuveen LLC now owns 90,951 shares of the biotechnology company’s stock worth $2,625,000 after purchasing an additional 1,878 shares during the period. State of Wyoming lifted its holdings in shares of Capricor Therapeutics by 76.0% in the 4th quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock worth $128,000 after purchasing an additional 1,913 shares in the last quarter. Finally, GoalVest Advisory LLC bought a new position in shares of Capricor Therapeutics in the 4th quarter worth $59,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.